Financial Performance - Revenue increased by approximately 1.6% to about RMB 74.7 million for the year ending December 31, 2024, compared to RMB 73.5 million for the year ending December 31, 2023[4] - Loss before tax was approximately RMB 30.1 million, worsening from a loss of approximately RMB 7.2 million for the year ending December 31, 2023[4] - Loss attributable to equity holders of the company was approximately RMB 32.4 million, compared to a loss of approximately RMB 13.6 million for the year ending December 31, 2023[4] - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 5.57 cents, compared to RMB 2.27 cents for the year ending December 31, 2023[4] - Total comprehensive loss for the year was RMB 31.146 million, compared to RMB 12.206 million for the previous year[6] - The group reported a pre-tax loss of RMB 49,280,000 for 2024, compared to RMB 32,074,000 in 2023, indicating an increase in losses[24] - The net loss for the fiscal year ending December 31, 2024, was approximately RMB 32.6 million, compared to a net loss of RMB 13.6 million for the fiscal year ending December 31, 2023, indicating a significant increase in losses[39] Revenue Breakdown - Revenue from customer contracts for 2024 was RMB 74,680,000, an increase of 1.6% from RMB 73,513,000 in 2023[21] - Revenue for the reporting period was approximately RMB 74.7 million, an increase of about 1.6% compared to the fiscal year ending December 31, 2023, primarily due to contributions from two new facilities[54] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 30.5 million, a decrease of about 2.2% compared to the previous fiscal year, accounting for approximately 40.8% of total revenue[55] - Revenue from the Orthodontics Department was approximately RMB 14.1 million, a decrease of about 2.1% compared to the previous fiscal year, representing about 18.9% of total revenue[56] - Revenue from the Oral Rehabilitation Department was approximately RMB 16.3 million, an increase of RMB 1.4 million, accounting for about 21.8% of total revenue[57] - Revenue from the Implant Dentistry Department was approximately RMB 8.9 million, an increase of about 11.3% compared to the previous fiscal year, indicating a recovery in revenue[58] Expenses and Costs - Gross profit decreased to RMB 26.976 million from RMB 32.655 million, reflecting a decline in profitability[6] - Administrative expenses increased significantly to RMB 36.733 million from RMB 22.940 million, indicating rising operational costs[6] - Sales costs increased by approximately 16.6% to about RMB 47.7 million, attributed to rising employee costs and stock issuance rewards[59] - Selling expenses increased by approximately 10.1% to about RMB 22.8 million, mainly due to increased marketing and promotional expenses[62] - Employee benefits expenses increased to approximately RMB 52.2 million during the reporting period, compared to approximately RMB 33.4 million in the fiscal year 2023, an increase of RMB 18.8 million[72] Assets and Liabilities - Non-current assets increased to RMB 91,889 thousand in 2024 from RMB 80,117 thousand in 2023, representing a growth of 14.5%[8] - Current assets decreased to RMB 98,265 thousand in 2024 from RMB 152,310 thousand in 2023, a decline of 35.5%[8] - Total liabilities increased to RMB 69,756 thousand in 2024 from RMB 66,882 thousand in 2023, reflecting a rise of 4.2%[9] - The company's net asset value decreased to RMB 120,398 thousand in 2024 from RMB 165,545 thousand in 2023, a drop of 27.2%[9] - Cash and cash equivalents decreased to RMB 78,494 thousand in 2024 from RMB 86,827 thousand in 2023, a reduction of 9.5%[8] - The company reported a total equity of RMB 120,398 thousand in 2024, down from RMB 165,545 thousand in 2023, indicating a decrease of 27.2%[9] Taxation - The group's income tax expense for the fiscal year 2024 was RMB 2,478 thousand, a decrease from RMB 6,448 thousand in 2023[29] - The group has no income tax liabilities in Hong Kong for the fiscal year 2024 due to no taxable profits generated[8] - The group has a deferred tax expense of RMB 459 thousand for the fiscal year 2024, down from RMB 4,511 thousand in 2023[29] Corporate Governance and Shareholder Information - The board has resolved not to recommend the payment of a final dividend for the year ending December 31, 2024, compared to a dividend of HKD 0.01 per share for the year ending December 31, 2023[4] - The annual general meeting is scheduled for June 18, 2025, with a suspension of share transfer registration from June 13 to June 18, 2025[82][83] - The company has complied with all corporate governance codes applicable as of December 31, 2024, except for one specific provision[84] - The audit committee consists of three independent non-executive directors, who have reviewed the annual consolidated financial statements for the year ending December 31, 2024[89] Strategic Initiatives - The group is adjusting its business to respond to the national dental procurement policy, which has expanded to orthodontics, pediatric dentistry, and cosmetic dentistry[49] - The group aims to optimize its service offerings and strengthen partnerships with upstream suppliers to maintain service quality while achieving cost efficiency[49] - The group plans to enhance community-centered initiatives, including expanding oral health education programs and supporting vulnerable groups in collaboration with local governments[50] - The group is committed to reducing waste in clinical operations and promoting digital patient engagement tools[50] - The group is strategically investing in scalable technologies and standardized processes to ensure adaptability in a rapidly changing regulatory environment[49] - The group is focused on optimizing its cost structure to attract price-sensitive patients while ensuring service quality[41] - The group is establishing long-term partnerships with dental material suppliers to obtain better purchasing prices and improve internal management efficiency[41]

美 皓 醫 療 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 三 月 二 十 八 日（星 期 五）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考 慮 及批准本公司及其附屬公司截至二零二四年十二月三十一日止年度之年度業 績 及 其 刊 發，以 及 考 慮 建 議 派 發 末 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 董事會會議日期 承董事會命 美皓醫療集團有限公司 主席兼執行董事 王曉敏 香 港，二 零 二 五 年 三 月 十 二 日 於 本 公 告 日 期，執 行 董 事 為 ...

美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 盈利警告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 不 會 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Meihao Medical Group Co., Ltd (i) 持 續 受 到 種 植 牙 集 採 政 策 影 響，銷 售 價 格 大 幅 度 降 低，進 一 步 縮 減 植 牙 服 務 的 利 潤 空 間； (ii) 本 地 口 腔 市 場 競 爭 激 烈，行 業 內 的 價 格 戰 和 過 度 競 爭 加 劇 了 盈 利 壓 力，導 致 新 客 戶 開 發 成 本 變 高，缺 乏 有 效 的 客 源 渠 道，且 轉 化 率 不 穩 定； 儘 管 現 況 如 此，本 集 團 仍 保 持 了 良 好 財 務 狀 況，公 司 現 金 儲 備 充 足。董 事 會 將 繼 續 評 估 具 有 挑 戰 ...

Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 董事名單與其角色職能 美 皓 醫 療 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）成 員 載 列 如 下： 執行董事 王曉敏先生 （主 席） 鄭蠻女士 周健醫生 獨立非執行董事 譚漢珊女士 張永存先生 董 事 會 下 設 三 個 委 員 會，該 等 委 員 會 的 成 員 載 列 如 下： | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董 事 | | | | | | 王曉敏先生 | | – | M | C | | 鄭蠻女士 | | – | – | – | | 周健醫生 | | – | – | – | | 黃晞華先生 | | C | M | – | | 譚漢珊女士 | | M | C | M | | 張永存先生 | | M | – | M | 附 註： C: 有關董事委員會的主席 M: 有關董事委員會的成員 香 港，二 零 二 四 年 十 一 月 二 十 ...

Meihao Medical Group Co., Ltd 美皓醫療集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：1947） （於開曼群島註冊成立的有限公司） (1)董 事 調 任； (2)委 任 獨 立 非 執 行 董 事； 及 (3)審核委員會及提名委員會成員變動 (1) 董事調任 美 皓 醫 療 集 團 有 限 公 司（「本公司」，連 同 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈，自 二 零 二 四 年 十 一 月 二 十 九 日 起，周 健 醫 生 （「周醫生」）已 由 獨 立 非 執 行 董 事 調 任 為 執 行 董 事，並 不 再 為 本 公 司 審 核 委 員 會（「審核委員會」）成 員 及 本 公 司 提 名 委 員 會（「提名委員會」）成 員。 周 醫 生 的 履 歷 詳 情 如 下： 周 醫 生，69歲 ...

美皓醫療集團有限 公司 M EIH AO M E DIC AL G R O UP C O., LT D 美 皓 醫 療 集 團 有 限公司 MEIHAO MEDICAL GROUP CO., LTD (Incorporated in the Cayman Islands with limited liability) Stock Code: 1947 INTERIM REPORT 2024 中期報告 （於開曼群島註冊成立的有限公司） 股份代號 : 1947 中期報告 2024 2024 INTERIM REPORT and . tes and of the state of the many of the state of the states of the states of the states of the states of the states of the states of the states of the states of the state o 目錄 | --- | --- | |-------|--------------------------| | | | | 2 | 公司資料 | ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 33,797, a decrease of 3.4% from RMB 34,985 for the same period in 2023[3] - Gross profit for the same period was RMB 12,348, down 20.5% from RMB 15,468 in 2023[3] - The company reported a loss before tax of RMB 14,432, compared to a loss of RMB 2,751 in the previous year, indicating a significant increase in losses[3] - Total comprehensive loss for the period was RMB 14,466, compared to a comprehensive income of RMB 1,005 in the same period last year[4] - The company reported a basic and diluted loss per share of RMB 2.51, compared to RMB 0.35 in the previous year, indicating a worsening financial performance[3] - The company reported a basic loss per share attributable to ordinary equity holders of RMB 15,074 thousand for the six months ended June 30, 2024, compared to RMB 2,122 thousand for the same period in 2023, indicating a significant increase in losses[20] - Revenue decreased from RMB 35.0 million for the six months ended June 30, 2023, to RMB 33.8 million for the six months ended June 30, 2024, representing a decline of approximately 3.4%[23] Assets and Liabilities - Non-current assets decreased to RMB 78,172 as of June 30, 2024, from RMB 80,117 as of December 31, 2023[5] - Current assets totaled RMB 146,254, a slight decrease from RMB 152,310 at the end of 2023[5] - The company's cash and cash equivalents increased to RMB 100,462 from RMB 86,827 at the end of 2023, reflecting improved liquidity[5] - Total liabilities increased to RMB 44,255 from RMB 37,959, indicating a rise in financial obligations[5] - The equity attributable to the owners of the parent decreased to RMB 151,504 from RMB 165,178, reflecting a decline in shareholder value[7] - Trade receivables at the end of the reporting period totaled RMB 1,317,789 thousand, a decrease from RMB 1,301,759 thousand as of December 31, 2023[21] - Trade payables at the end of the reporting period amounted to RMB 7,360,000 thousand, up from RMB 6,640,000 thousand as of December 31, 2023, reflecting an increase of approximately 10.9%[22] Revenue Breakdown - Customer contract revenue for the six months ended June 30, 2024, was RMB 33,797 thousand, a decrease of 3.4% from RMB 34,985 thousand in the same period of 2023[12] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 14.3 million, a decrease of about 4.7% year-on-year, accounting for approximately 42.2% of total revenue[36] - Revenue from the Orthodontics Department was approximately RMB 5.7 million, a decrease of about 6.6% year-on-year, representing about 17.0% of total revenue[37] - Revenue from the Oral Restoration Department was approximately RMB 7.1 million, a decrease of 1.4%, accounting for about 21.0% of total revenue[38] - Revenue from the Implant Department increased to approximately RMB 4.3 million, an increase of RMB 0.4 million or 10.3% year-on-year[39] Operational Changes - The total number of active patients decreased from 30,366 to 29,259, a reduction of 3.6% over the same period[27] - The number of active patients at Wenzhou Hospital decreased from 18,908 to 14,545, a decline of approximately 23.2%[27] - The company operates six private dental hospitals and clinics in Wenzhou, Zhejiang Province, focusing on comprehensive dental services across four main areas[23] - The company has increased advertising expenses to attract more customers in response to the impact of the implant dental collection policy on profit margins[23] - The company has implemented a talent acquisition strategy to ensure sustainable development and maintain existing human resources[23] - The implementation of the dental implant collection policy in China has led to a decrease in the number of visits and average spending per visit, posing long-term challenges for dental service providers[29] Future Strategies - The company is optimistic about its future development prospects despite the current challenges[23] - The company plans to increase investment in marketing efforts to capture market opportunities and strengthen its market position[29] - The company aims to expand its service offerings by establishing specialized pediatric dental hospitals to meet rising demand in Wenzhou[30] - Strategic acquisitions are being sought in Zhejiang Province and neighboring provinces to enhance market presence[30] - The company is focusing on upstream investments in medical device companies to stabilize supply chains and reduce procurement costs[31] - Upgrading the business operation software system will improve data integration and management across six dental hospitals and clinics, enhancing service efficiency[33] - Increased advertising investment is expected to improve business capabilities and customer engagement[33] Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and has adopted all applicable corporate governance codes, except for a specific provision regarding the separation of the roles of chairman and CEO[60][61] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim results for the six months ending June 30, 2024, ensuring compliance with accounting policies and disclosure requirements[64] - The interim report for the six months ending June 30, 2024, will be sent to shareholders and published on the company's website[65] - The company expresses heartfelt thanks to shareholders, management team, employees, and business partners for their support and contributions[66] Employee and Operational Metrics - The company has 323 employees as of June 30, 2024, an increase from 286 employees as of December 31, 2023[53] - Employee benefits expenses for the reporting period amounted to approximately RMB 19.1 million, a decrease of about RMB 1.1 million compared to RMB 20.2 million in the same period of 2023[54] Shareholder Information - The company declared a final dividend of HKD 0.01 per ordinary share, with approximately HKD 5.9 million (approximately RMB 5.4 million) to be paid in cash[19] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2024, consistent with the previous period[59] - The company completed a global offering of 150,000,000 shares at an issue price of HKD 0.84 per share, which is expected to support future business development and expansion in China[48] - The company issued 154,350 shares of bonus shares on June 26, 2024, which began trading on the Hong Kong Stock Exchange on August 15, 2024[56] - The company implemented a share reward plan on January 16, 2024, purchasing a total of 230,000 shares from January 24 to January 25, 2024, representing approximately 0.038% of the total issued shares[57] - The company completed the acquisition of 98.5% of the shares of a private dental service provider, Le Qing Dental Hospital Limited, on December 19, 2023[58] Risk Management - The company is closely monitoring foreign exchange risks, particularly the impact of RMB and HKD exchange rate fluctuations on its financial position[50] - The company has no significant contingent liabilities or guarantees as of June 30, 2024, consistent with the previous year[52] - There were no significant investments or acquisitions during the reporting period[55]

Financial Performance - The company's revenue decreased from RMB 1,274 million to RMB 735 million, representing a decline of approximately 42.3%[9]. - The net loss for the year was approximately RMB 136 million, compared to a net profit of RMB 286 million in the previous year[16]. - Cash and cash equivalents as of December 31, 2023, were RMB 868 million, a decrease of about 3.0% from the previous year[9]. - The net asset value decreased from RMB 1,778 million in 2022 to RMB 1,655 million in 2023[9]. - Gross profit decreased by approximately 58.2% to about RMB 327 million, with a gross margin of approximately 44.4%[40]. - Other income and gains decreased by approximately 40.4% to about RMB 59 million, primarily due to a reduction in government subsidies[41]. - Selling expenses increased by approximately 13.7% to about RMB 207 million, mainly due to an increase in sales and marketing personnel[42]. - Administrative expenses decreased by approximately 15.2% to about RMB 229 million, influenced by the absence of listing expenses from the previous year[43]. - The company recorded a loss attributable to owners of approximately RMB 136 million, compared to a profit of RMB 285 million in the previous fiscal year[45]. Patient Activity and Services - The number of active patients at dental hospitals decreased from 63,659 to 50,324[9]. - The total number of active patients in the five private dental hospitals decreased from 63,659 as of December 31, 2022, to 50,324 as of December 31, 2023, representing a decline of approximately 20.9%[23]. - Total revenue from the five private dental hospitals was RMB 73,513,000 for the year ended December 31, 2023, down from RMB 127,408,000 for the year ended December 31, 2022[24]. - Wenzhou Hospital contributed the largest share of revenue, accounting for approximately 62.4% of total revenue in 2023, with revenue of RMB 45,820,000[25]. - The implementation of the dental implant collection policy in China has led to a decrease in the number of visits and average spending per visit in the implant department, negatively impacting short-term performance[26]. Strategic Initiatives and Growth Plans - The company aims to enhance its market position in China despite challenges from centralized procurement policies affecting implant prices[9]. - The company plans to adopt prudent financial management and cost control measures to drive business growth in the coming year[10]. - The company plans to expand its presence in Wenzhou by establishing more private dental hospitals and seeking strategic acquisitions in Zhejiang Province and neighboring provinces[27]. - The company aims to invest in upstream dental equipment and materials to ensure stable supply and reduce procurement costs, enhancing profit margins[28]. - The focus on children's dental services is expected to drive growth in the dental service market, as the demand from pediatric patients is anticipated to increase[27]. - The company is exploring investments in the medical aesthetics industry to broaden its business scope and increase revenue sources[28]. - The overall strategy includes enhancing brand building and customer satisfaction through comprehensive service offerings and multi-faceted investment directions[28]. Corporate Governance and Management - The board consists of five members, including two executive directors and three independent non-executive directors[98]. - The company has adopted a corporate governance code and believes it has complied with it during the reporting period, except for a specific deviation[90]. - The board of directors is responsible for overall leadership and strategic decision-making, with specific duties including the formulation of annual financial budgets and profit distribution plans[101]. - Independent non-executive directors play a crucial role in supervising the board and providing independent judgment, particularly in cases of potential conflicts of interest[102]. - The board has established three committees: the audit committee, remuneration committee, and nomination committee, each with defined terms of reference[122]. Environmental, Social, and Governance (ESG) Strategies - The report covers the fiscal year ending December 31, 2023, focusing on the group's environmental, social, and governance (ESG) strategies and performance[166]. - The group emphasizes the importance of balancing profitability with environmental and social impacts, aiming for sustainable development and corporate social responsibility[165]. - The board of directors is responsible for ensuring effective implementation of the ESG policies, with dedicated teams managing ESG matters across business segments[164]. - The group has conducted a comprehensive review of existing policies and practices to improve future performance in ESG areas[165]. - Key performance indicators (KPIs) are calculated based on international standards and emission factors as per the guidelines from the Hong Kong Stock Exchange[166]. Waste and Emissions Management - The total greenhouse gas emissions generated during the reporting period amounted to 1,164.3 tons of CO2 equivalent[191]. - The company aims to reduce or maintain the total greenhouse gas emissions density at 90% to 120% of the baseline year (2023) by the end of 2026[191]. - Water consumption during the reporting period was 9,988 cubic meters, with a water consumption density of 34.92 cubic meters per employee[193]. - The total hazardous waste generated was 18,580 kilograms, with a hazardous waste density of 64.97 kilograms per employee[196]. - The company has implemented measures to reduce greenhouse gas emissions, including water management and energy efficiency training for employees[192].

Financial Performance - Revenue decreased by approximately 42.3% to about RMB 73.5 million, compared to RMB 127.4 million for the year ended December 31, 2022[2]. - The company reported a loss before tax of approximately RMB 7.2 million, a decline from a profit of approximately RMB 40.2 million for the year ended December 31, 2022[2]. - Loss attributable to equity holders of the company was approximately RMB 13.6 million, compared to a profit of approximately RMB 28.5 million for the year ended December 31, 2022[2]. - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 2.27, down from earnings of approximately RMB 6.22 for the year ended December 31, 2022[5]. - The group reported a pre-tax loss of RMB 10,478 thousand for 2023, compared to a loss of RMB 15,204 thousand in 2022, indicating a reduction in losses[25]. - The company's gross profit decreased by approximately 58.2% to about RMB 32.7 million, with a gross profit margin dropping to approximately 44.4% from 61.4% in the previous year[71]. - Other income totaled RMB 5,859 thousand in 2023, down from RMB 9,895 thousand in 2022, primarily due to a significant reduction in government grants[24]. - Income tax expenses for the reporting period were approximately RMB 6.4 million, down from RMB 11.6 million for the year ending December 31, 2022, primarily due to a decline in group revenue and losses from several subsidiaries[76]. Assets and Liabilities - Total non-current assets increased to RMB 80,117,000 from RMB 76,211,000, representing a growth of 3.8% year-over-year[7]. - Current assets decreased to RMB 152,310,000 from RMB 176,507,000, a decline of 13.7% year-over-year[7]. - Total liabilities decreased from RMB 74,967,000 in 2022 to RMB 66,882,000 in 2023, a reduction of 10.7%[7]. - Net assets decreased to RMB 165,545,000 from RMB 177,751,000, reflecting a decline of 6.8% year-over-year[8]. - Cash and cash equivalents decreased to RMB 86,827,000 from RMB 89,529,000, a decrease of 3.1%[7]. - The company's equity attributable to owners remained stable at RMB 165,178,000 compared to RMB 177,372,000 in the previous year[8]. - Current assets decreased from approximately RMB 84.0 million as of December 31, 2022, to approximately RMB 7.0 million as of December 31, 2023, mainly due to the collection of RMB 67.1 million from the global offering[78]. - As of December 31, 2023, the group's current assets net value was approximately RMB 114.4 million, with a current ratio of 4.0 times, down from 4.3 times in the previous year[79]. Revenue Breakdown - Revenue from customer contracts for 2023 was RMB 73,513 thousand, a decrease of 42.4% from RMB 127,408 thousand in 2022[21]. - Revenue from the oral comprehensive treatment department was approximately RMB 31.2 million, a decrease of about 2.5% year-on-year, accounting for approximately 42.5% of total revenue during the reporting period[65]. - Revenue from the orthodontics department was approximately RMB 14.4 million, a decrease of about 27.6% year-on-year, representing about 19.7% of total revenue[66]. - Revenue from the oral restoration department was approximately RMB 14.9 million, a decrease of RMB 13.2 million or 47.0%, accounting for about 20.2% of total revenue[67]. - Revenue from the implant dentistry department was approximately RMB 8.0 million, a significant decrease of RMB 34.2 million or 81.0% due to the implementation of centralized procurement policies[68]. Operational Insights - The company operates primarily in the dental services sector, with all external revenue generated from customers in mainland China[17]. - The company operates five private dental hospitals in Wenzhou, Zhejiang Province, focusing on comprehensive dental services[40]. - The total number of active patients in the five private dental hospitals decreased from 63,659 as of December 31, 2022, to 50,324 as of December 31, 2023, representing a decline of approximately 20.9%[50]. - Wenzhou Hospital contributed the largest share of revenue, accounting for approximately 62.4% of total revenue in 2023, with revenue of RMB 45,820,000[53]. - The implementation of the dental implant procurement policy in China has led to a decrease in the number of dental visits and average spending per visit, negatively impacting the group's dental implant services in the short term[54]. - The company plans to continue expanding its market presence by establishing more private dental hospitals in Wenzhou and seeking potential strategic acquisitions in Zhejiang Province or neighboring provinces[57]. - The group aims to penetrate the pediatric dental market further, believing that demand from child patients will drive growth in the dental service market[57]. - The company is enhancing its operational software systems to improve data integration and management across its five dental hospitals, which will increase service efficiency and reduce operational costs[59]. - The group is focused on providing high-quality dental services to build a good reputation and gain customer trust, which is crucial for competitive advantage[59]. Strategic Initiatives - The board has proposed a final dividend of HKD 0.01 per ordinary share, compared to no dividend for the year ended December 31, 2022[2]. - The company intends to invest in upstream and downstream industry chain extensions to stabilize supply sources and reduce procurement costs, thereby enhancing overall competitiveness[58]. - The establishment of a dental training center is planned to cultivate in-house dental talent and improve service professionalism[62]. - The company is focusing on enhancing service quality and customer satisfaction to gain more customer trust and support, aiming for sustainable development[61]. - The group plans to use net proceeds from global offerings for business expansion and working capital, with no major investment plans set as of December 31, 2023[90]. Governance and Compliance - The company has adhered to all applicable corporate governance codes as of December 31, 2023, except for one specific provision[100]. - The audit committee consists of three independent non-executive directors, with Mr. Huang Xihua as the chairman[106]. - The annual report for the year ending December 31, 2023, will be sent to shareholders and published on the company's website at an appropriate time[107]. - The board expresses heartfelt thanks to shareholders, management team, employees, and business partners for their support and contributions[108].

智通财经APP讯，美皓集团(01947)发布公告，李忠成因其他工作安排已辞任公司公司秘书、公司根据香港联合交易所有限公司证券上市规则第3.05条的授权代表及根据上市规则第19.05(2)条及公司条例(香港法例第622章)第16部在香港代公司接受法律程序文件及通知的代理人，自2024年3月31日起生效。 李先生辞任后，董事会欣然宣布，陈玉颖已获委任为公司的公司秘书、授权代表及法律程序代理人，自2024年3月31日起生效。 ...